Corvus Pharmaceuticals, Inc. (CRVS) Discusses Phase 1 Clinical Trial Results of Soquelitinib in Atopic Dermatitis with Focus on Cohort 4 Transcript

Core Viewpoint - The conference call is hosted by Corvus Pharmaceuticals, featuring key executives discussing company updates and future outlooks [3][4]. Group 1: Company Overview - The call includes participation from Dr. Richard Miller (CEO), Leiv Lea (CFO), Jeff Arcara (CBO), Dr. Ben Jones (SVP of Pharmaceutical Development), and Dr. Suresh Mahabhashyam (VP of Clinical Development) [3]. Group 2: Call Structure - The executive team will provide prepared remarks followed by a question-and-answer session, indicating a structured approach to communication with stakeholders [4].